7480-33-3

Upstream product

• 18903-44-1 2-amino-2,2-diphenylethan-1-ol 
• 105-58-8 Diethyl carbonate 
• 51707-34-7 3-hydroxy-2,2-diphenyl-propionic acid hydrazide 
• 616-38-6 carbonic acid dimethyl ester 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 3060-50-2 2,2-diphenylglycine 
• 76-93-7 Benzilic acid 
• 100-58-3 phenylmagnesium bromide 

Downstream Products

• 681035-25-6 (2-oxo-4,4-diphenyl-oxazolidin-3-yl)-phosphonic acid diethyl ester 
• 327025-35-4 (R)-3-(3-cyclohexyl-3-phenylpropanoyl)-4,4-diphenyl-2-oxazolidinone 
• 327025-33-2 (R)-3-(4,4-dimethyl-3-phenylpentanoyl)-4,4-diphenyl-2-oxazolidinone 

Relevant academic research and scientific papers

A Short Access to Symmetrically α,α-Disubstituted α-Amino Acids from Acyl Cyanohydrins

A straightforward synthesis of symmetrically α,α-disubstituted α-amino acids is presented. The key step of this process relies on the efficient double addition of Grignard reagents to acyl cyanohydrins to provide N-acyl amino alcohols selectively in good yields. The chemoselectivity of the reaction was modulated by the nature of the acyl moiety. Eleven amino acids were prepared, including the particularly simple divinylglycine, which is not easily accessible by using conventional methods.

N-Phosphoryl oxazolidinones as effective phosphorylating agents

A number of N-phosphoryl oxazolidinones have been prepared and evaluated, the best being 5,5-diphenyl oxazolidinones, the utility of which was demonstrated in the phosphorylation of a number of representative primary, secondary, tertiary, and phenolic alcohols.

Unprecedented effects of achiral oxazolidinones on enantioselective radical-mediated conjugate additions using a chiral zinc triflate

equation presented A role of achiral oxazolidinones to enhance the enantioselectivity in reactions of N-cinnamoyloxazolidinones with alkyl radicals promoted by a chiral Lewis acid is described. Efficient enantioselective radical-mediated conjugate additio

Oxazolidinones as alpha 1A receptor antagonists

This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.